ホルモノネチンは,JUNを阻害し,ILC2細胞によるII型免疫反応を抑制することで,アレルギー性喘息を緩和します
Jian Liu1, Yanyan Li2, Meng Liu1
1Respiratory Department, Beijing Traditional Chinese Medicine Hospital, Capital Medical University, Beijing 100010, China.
Molecular immunology
|August 20, 2025
まとめ
フォルモノネチン (FM) は,呼吸道炎症と粘液を減少させることで,アレルギー性喘息を効果的に治療します. JUN遺伝子を抑制することで,II型免疫反応と細胞移動を標的とする.
科学分野:
- 免疫学
- 薬理学について
- 呼吸器医学
背景:
- アレルギー性喘息 (AS) は,呼吸道炎症と過敏性によって特徴づけられる慢性呼吸器疾患である.
- II型先天性リンパ球 (ILC2) はアレルギー性喘息の病原性において重要な役割を果たします.
- 自然なフラボノイドであるホルモノネチン (FM) は,抗炎症的性質を示しています.
研究 の 目的:
- アレルギー性喘息 (AS) のマウスモデルにおけるホルモネチン (FM) の治療の可能性を調査する.
- ILC2sとJUN遺伝子を中心に,FMの作用の根本的なメカニズムを解明する.
主な方法:
- オバルブミン (OVA) 誘発のマウスモデルが確立され,FMで治療された.
- 呼吸道炎症,粘液分泌,およびILC2の活性化/移動の評価は,組織学,ELISA,およびフローサイトメトリーを用いて行う.
- 分子分析とJUNアゴニスト (15(S) -HpETEを用いたJUN遺伝子の役割の調査; in vitroアッセイでは,ILC2sに対するFMの影響を評価した.
主要な成果:
- FM治療は,ASマウスにおける呼吸道炎症を大幅に軽減し,粘液過剰分泌を減少させ,血清IgEレベルを低下させた.
- FMは,関連サイトカインと転写因子の発現を抑制し,ILC2sの豊富さ,活性化,および肺-腸軸の移動を減少させた.
- インビトロ試験では,IFC2の増殖と活性化を抑制し,JUNに依存するメカニズムを示す15- S- HpETEによって効果が逆転した.
結論:
- FORMONONETIN (FM) は,JUN遺伝子を標的として,II型免疫反応とILC2の移行を抑制することによって,アレルギー性喘息 (AS) を改善します.
- FMは,ILC2媒介の炎症を調節することで,喘息の治療薬としての潜在能力を示しています.
さらに関連する動画
08:25An Ex vivo Mast Cell Degranulation Assay using Crude Peritoneal Exudate Cells and Natural Antigen Stimulation
Published on: April 27, 2021
2.5K
10:39Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy
Published on: April 16, 2019
7.7K
関連する概念動画
01:19Antiasthma Drugs: Leukotriene Modifiers
463
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
463
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
453
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
453
01:20Asthma: Pathogenesis and Management
581
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
581
01:17Drugs Used in Lower Respiratory Disorders: Overview
578
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
578
01:26Asthma-II: Pathophysiology and Classification
2.8K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.8K
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
452
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
452